GMP-certified biomanufacturing

Medicine security, engineered end to end.

Adjuvant Bio develops, manufactures, and distributes generic and biosimilar therapeutics at national scale, from bulk drug substance to the pharmacy shelf.

Explore the catalog View the pipeline

Products in market

Units per year

Markets served

GMP CertifiedISO 13485WHO PrequalifiedSerialization ReadyGDP DistributionPharmacovigilance 24/7Data Integrity ALCOA+

The Mandate

A sovereign supply of essential medicine.

When a supply chain is national infrastructure, it cannot depend on someone else's factory. Adjuvant Bio owns the whole chain: molecule to vial to distribution, under one quality system.

Read the mandate →

Portfolio

Products in market

Output

Units per year

Footprint

GMP facilities

Reach

Markets served

The Network

Nine time zones, one cold chain.

Product leaves the fill-finish line and stays inside a monitored 2 to 8 °C envelope until a pharmacist opens the carton. Every leg of that journey reports its own temperature.

Sovereign capacity

Enough installed volume to cover national demand for the essential-medicines list without importing finished product.

Continuous telemetry

Every pallet carries a logger. Excursions raise a case before the shipment reaches its next hop.

Development Pipeline

Therapeutic development pipeline.

Five programmes from discovery to registration. Hover any row for its mechanism, target population and enrollment.

ADJ-201

Type 2 Diabetes

Marketed

Active

Mechanism: Biguanide, hepatic glucose output suppression
Population: Adults with type 2 diabetes
Enrollment: Marketed, 8 territories

ADJ-330

Rheumatoid Arthritis

Registration

Active

Mechanism: Anti-TNF monoclonal antibody (biosimilar)
Population: Moderate to severe RA
Enrollment: Dossier under review

ADJ-415

HER2+ Breast Cancer

Phase III

Active

Mechanism: Anti-HER2 monoclonal antibody (biosimilar)
Population: HER2-positive metastatic breast cancer
Enrollment: ~640 patients enrolled

ADJ-508

Chronic Kidney Disease

Phase II

Enrolling

Mechanism: Long-acting erythropoiesis-stimulating peptide
Population: Anemia of chronic kidney disease
Enrollment: ~180 patients enrolling

ADJ-622

Severe Asthma

Phase I

Planning

Mechanism: Inhaled anti-IL-5 biologic
Population: Severe eosinophilic asthma
Enrollment: First-in-human, dose escalation

Our Science

From candidate to commercial supply.

The same platform carries a molecule through discovery, into a characterised process, and out to a line that can run it every week.

Stage 01

Discovery

Candidate selection runs against a structural library and an in-house assay panel. Most things fail here, which is the point.

Stage 02

Characterisation

Higher-order structure, glycan profile, and impurity fate are pinned down before a process is locked. A biosimilar is only as good as the analytics behind it.

Stage 03

Manufacture

The locked process moves to a line that reproduces it batch after batch, under one quality system and one set of release specifications.

Infrastructure

Four sites, one quality system.

Bulk Drug Substance Plant

Calder Vale, Northmoor

Mammalian cell culture, up to 6 × 2,000 L single-use bioreactors.

12,000 L installedGrade C/D cleanroomsContinuous perfusion ready

Sterile Fill-Finish

Calder Vale, Northmoor

Vial and pre-filled syringe lines under isolator technology.

120M units/yrGrade A isolators100% automated inspection

Quality Control Campus

Ashcombe, Northmoor

Release and stability testing, method development, microbiology.

Mass spec suiteGMP micro lab24/7 stability chambers

Distribution & Cold Chain

Wrenport, Eastreach

2-8 °C and -20 °C national distribution with live telemetry.

40,000 pallet positionsGDP certifiedIoT-monitored

Strategic Partnering

The advantage of a single, integrated partner.

One quality system from molecule to market means fewer handoffs, fewer interfaces, and a shorter path to supply. Partners plug into a chain that is already built.